CD00509

CD00509 is a tyrosyl-DNA phosphodiesterase (PDE) Tdp1 inhibitor with an IC50 of 0.71 μM. CD00509 increases DNA damage and promotes apoptosis of MCF-7 cells. CD00509 can sensitize breast cancer cells and wild-type murine embryonic fibroblasts (MEFs) to Camptothecin (CPT) (HY-16560) . CD00509 can be used for the study of cancers such as breast cancer[1][2][3].

Product Specifications

CAS Number

[27430-18-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Caspase; DNA/RNA Synthesis; Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cd00509.html

Purity

98.0

Solubility

DMSO : 12.5 mg/mL (ultrasonic)

Smiles

S=C1NC(=O)C(C(N1)=O)=CC2=CC=CO2

Molecular Formula

C9H6N2O3S

Molecular Weight

222.22

Precautions

H302, H315, H319, H335

References & Citations

[1]Laev SS, et al. Tyrosyl-DNA phosphodiesterase inhibitors: Progress and potential. Bioorg Med Chem. 2016 Nov 1;24 (21) :5017-5027.|[2]Dean RA, et al. Identification of a putative Tdp1 inhibitor (CD00509) by in vitro and cell-based assays. J Biomol Screen. 2014 Dec;19 (10) :1372-82.|[3]Dean RA, et al. Identification of a putative Tdp1 inhibitor (CD00509) by in vitro and cell-based assays. J Biomol Screen. 2014 Dec;19 (10) :1372-82. |[4]Segerer G, et al. An essential developmental function for murine phosphoglycolate phosphatase in safeguarding cell proliferation. Sci Rep. 2016 Oct 12;6:35160.